{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:33:48Z","timestamp":1784342028524,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Swiss National Foundation","award":["31-130748"],"award-info":[{"award-number":["31-130748"]}]},{"name":"Swiss National Foundation","award":["310030_146295\/1"],"award-info":[{"award-number":["310030_146295\/1"]}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.cmi.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:27:55Z","timestamp":1531841275000},"page":"512.e7-512.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model"],"prefix":"10.1016","volume":"25","author":[{"given":"A.","family":"Tarnutzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Z\u00fcrcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Norrby-Teglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Sch\u00fcpbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Zinkernagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.07.007_bib1","first-page":"1","article-title":"Necrotizing fasciitis: risk factors of mortality","volume":"8","author":"Khamnuan","year":"2015","journal-title":"Risk Manag Healthc Policy"},{"key":"10.1016\/j.cmi.2018.07.007_bib2","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2015.20.18.21117","article-title":"Clindamycin resistant emm33 Streptococcus pyogenes emerged among invasive infections in Helsinki metropolitan area, Finland, 2012 to 2013","volume":"20","author":"Pesola","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2018.07.007_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.02208-10","article-title":"Emergence of erythromycin- and clindamycin-resistant Streptococcus pyogenes emm 90 strains in Hawaii","volume":"49","author":"Chen","year":"2011","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2018.07.007_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001090.pub2","article-title":"Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock","author":"Alejandria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2018.07.007_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","article-title":"Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial","volume":"37","author":"Darenberg","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/cid\/ciu449","article-title":"Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study","volume":"59","author":"Linner","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/00365540410020866","article-title":"Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach","volume":"37","author":"Norrby-Teglund","year":"2005","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib8","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00134-017-4786-0","article-title":"Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial","volume":"43","author":"Madsen","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2018.07.007_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/cid\/ciu304","article-title":"Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections","volume":"59","author":"Carapetis","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2958.2011.07709.x","article-title":"From transcription to activation: how group A Streptococcus, the flesh-eating pathogen, regulates SpeB cysteine protease production","volume":"81","author":"Carroll","year":"2011","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2018.07.007_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrmicro2648","article-title":"Molecular insight into invasive group A streptococcal disease","volume":"9","author":"Cole","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cmi.2018.07.007_bib12","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/IAI.68.6.3523-3534.2000","article-title":"Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases","volume":"68","author":"Chatellier","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2018.07.007_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2958.2003.03797.x","article-title":"Invasive M1T1 group A Streptococcus undergoes a phase-shift in\u00a0vivo to prevent proteolytic degradation of multiple virulence factors by SpeB","volume":"51","author":"Aziz","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2018.07.007_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nm1612","article-title":"DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection","volume":"13","author":"Walker","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2018.07.007_bib15","first-page":"269","article-title":"Clindamycin affects group A Streptococcus virulence factors and improves clinical outcome","volume":"215","author":"Andreoni","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.chom.2008.07.002","article-title":"The IL-8 protease SpyCEP\/ScpC of group A Streptococcus promotes resistance to neutrophil killing","volume":"4","author":"Zinkernagel","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.cmi.2018.07.007_bib17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2958.1998.00681.x","article-title":"Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci","volume":"27","author":"Ruiz","year":"1998","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.cmi.2018.07.007_bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cub.2005.12.039","article-title":"DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps","volume":"16","author":"Buchanan","year":"2006","journal-title":"Curr Biol"},{"key":"10.1016\/j.cmi.2018.07.007_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081298","article-title":"Streptococcal SpeB cleaved PAR-1 suppresses ERK phosphorylation and blunts thrombin-induced platelet aggregation","volume":"8","author":"Ender","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2018.07.007_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/381979","article-title":"Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome","volume":"38","author":"Darenberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/00365540310015944","article-title":"Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections","volume":"35","author":"Norrby-Teglund","year":"2003","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib22","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1128\/IAI.66.5.2279-2283.1998","article-title":"Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections","volume":"66","author":"Basma","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2018.07.007_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkl173","article-title":"Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation","volume":"58","author":"Sriskandan","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2018.07.007_bib24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1086\/315198","article-title":"Lack of benefit of intravenous immune globulin in a murine model of group A streptococcal necrotizing fasciitis","volume":"181","author":"Patel","year":"2000","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2018.07.007_bib25","first-page":"515825","article-title":"Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin","author":"Reglinski","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2018.07.007_bib26","unstructured":"US Centers for Disease Control and Prevention. Rabies postexposure prophylaxis (PEP) schedule. Available at: https:\/\/www.cdc.gov\/rabies\/medical_care\/index.html."},{"key":"10.1016\/j.cmi.2018.07.007_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12010-017-2624-z","article-title":"Production and characterization of F(ab\u2032)2 fragments obtained by enzymatic digestion from murine anti-MRSA PBP2a monoclonal antibodies","volume":"185","author":"de Araujo","year":"2018","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.cmi.2018.07.007_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1423-0410.1995.tb02536.x","article-title":"Pharmacokinetics of single and multiple infusions of 5S intravenous immunoglobulin","volume":"68","author":"Theobald","year":"1995","journal-title":"Vox Sang"},{"key":"10.1016\/j.cmi.2018.07.007_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1153","article-title":"IVIG-mediated protection against necrotizing pneumonia caused by MRSA","volume":"8","author":"Diep","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cmi.2018.07.007_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00968-17","article-title":"Commercial intravenous immunoglobulin preparations contain functional neutralizing antibodies against the Staphylococcus aureus leukocidin LukAB (LukGH)","volume":"61","author":"Wood","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.07.007_bib31","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1128\/AAC.00463-16","article-title":"Modulation of Staphylococcus aureus biofilm matrix by subinhibitory concentrations of clindamycin","volume":"60","author":"Schilcher","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2018.07.007_bib32","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome\u2014a comparative observational study. The Canadian Streptococcal Study Group","volume":"28","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18305226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18305226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:45Z","timestamp":1761117705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18305226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1198743X18305226"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.07.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}